Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes.
about
Identifying candidate drivers of drug response in heterogeneous cancer by mining high throughput genomics data.The Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle.Agrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma.Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilizationEMDomics: a robust and powerful method for the identification of genes differentially expressed between heterogeneous classes.Biomarkers to assess the efficiency of treatment with platinum-based drugs: what can metallomics add?Tumor matrix protein collagen XIα1 in cancer.The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.Proteomic profiling of the cancer cell secretome: informing clinical research.Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.Recently identified drug resistance biomarkers in ovarian cancer.Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications.Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics.Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis.Prediction of therapy response in ovarian cancer: Where are we now?
P2860
Q31121773-9BDDB469-AA78-4B1D-969B-EE7561BE5A09Q33361929-C7FD434A-E983-4C89-9995-1AD54A5CA183Q35519929-4239F7CE-1AD6-4F91-9993-0F2F701B2AF7Q36182116-9194DD45-65C2-4C2D-8837-225539BAC67CQ36414284-B7D122C8-860C-42A8-B635-CB3550D7B26CQ36551085-E6E11801-0134-443A-9FB1-A113EDBBD85BQ38267182-4EADB2C0-9854-4516-B112-257185BC087FQ38289649-119ED3D7-0482-4998-BA17-C70945CBA71EQ38654867-A9921709-4857-42C3-9830-C14DE6D62CD1Q38659528-035467FC-574A-44F6-B175-8B7BB10FDA03Q38714246-E73DABDF-E806-4C56-AD8C-37D8E9A8D6EFQ38741073-00EB20FE-3FE0-4F16-B0F8-F8256642AAA2Q38748131-CB964745-D9E7-4F1D-A6E5-0CFFA56BE787Q38816181-49A7A1EF-79C6-4B1A-9A05-769A4CEEF9F2Q38958066-EE05BCD0-D91E-45D5-BB5E-911682003EF7Q39263260-3112F6E3-ABC6-489B-8D19-7A6340E15078
P2860
Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Identification of candidate ci ...... ian carcinoma cell secretomes.
@en
Identification of candidate ci ...... ian carcinoma cell secretomes.
@nl
type
label
Identification of candidate ci ...... ian carcinoma cell secretomes.
@en
Identification of candidate ci ...... ian carcinoma cell secretomes.
@nl
prefLabel
Identification of candidate ci ...... ian carcinoma cell secretomes.
@en
Identification of candidate ci ...... ian carcinoma cell secretomes.
@nl
P2093
P2860
P356
P1476
Identification of candidate ci ...... ian carcinoma cell secretomes.
@en
P2093
C A Hamilton
G L Maxwell
K A Conrads
T P Conrads
P2860
P2888
P304
P356
10.1038/BJC.2013.687
P407
P577
2013-10-31T00:00:00Z